FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BLICKENSTAFF KIM D				TA	2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM]									5. Relationship of Repor (Check all applicable) X Director Officer (give titl			10% Owi		Owner	
(Last) (First) (Middle) C/O TANDEM DIABETES CARE, INC. 11075 ROSELLE STREET					3. Date of Earliest Transaction (Month/Day/Year) 08/16/2021										below			belov		
(Street) SAN DIEGO CA 92121 (City) (State) (Zip)				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution D if any (Month/Day/		oate,	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				5. Amo Securit Benefic Owned Followi		es ally		Direct ct (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amo	unt	(A) or (D)	Pri	ice		Reported Transaction(s) (Instr. 3 and 4)		,				
Common Stock			08/16/2021				S		24,	,240	D	\$109.0698(3 (1)	228,150		I		See Footnote ⁽²⁾	
Common Stock			08/17/2021				S		6,5	510	D	\$108.0866 ⁽³⁾		5 ⁽³⁾	221,640		I		See Footnote ⁽²⁾	
Common	Stock		08/17/2021				s		19,	,250	D	\$1	109.1249	9(4) 1 202 390 T T T			See Footnote ⁽²⁾			
Common	Stock													1,89		892		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)	action		mber ative rities ired osed	hber 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Ir 3 and 4)					le and unt of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D) or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)	(D)	Date Exercis	sable	Expira Date		Title	Amount or Number of Shares							

Explanation of Responses:

- 1. The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$109.00 to \$109.46. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- 2. The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.
- 3. The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$108.00 to \$108.88. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- 4. The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$109.10 to \$109.13. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.

Remarks:

s/ David B. Berger, Attorney-08/18/2021 in-Fact for Kim D.

Blickenstaff

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.